Pfizer Acquires a Stem-Cell Therapy

Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in stem cells.

Pfizer will have the rights to develop Athersys’s cells to treat inflammatory bowel disease, the companies are expected to announce on Monday. It will pay Athersys $6 million initially and up to $105 million in the future.

read more:

Incoming search terms:

stemgenex complaints, stemgenex reviews, stemgenex cost, Athersys Fraud, stemgenex review, reviews of stemgenex, stemgenex MS reveiws, is stemgenex legit, stemgenex fraud, pfizer and stem cells, stem genex review, stemgenex paient complaints, stemgenex customer complaints, stemgenex testimonials, stemedix complaints com, stem genex ms reviews, reviews from patients that had procedure at Stemgenex, reveiws on stem genex, pfizer stem cell therapy 2014, pfizer stem cell research, Pfizer cell therapy, stemgenex testimonials ms.

One thought on “Pfizer Acquires a Stem-Cell Therapy”

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>